It is worth noting, that through a deep understanding of the dysregulation of specific genes and pathways, targets such as downstream effectors of KLF4, 5, and 15, which are involved in hypertrophy and fibrosis, may be new avenues for treatment in conditions such as diabetic cardiomyopathy and heart failure. The gene discussed is KLF4; the disease is diabetic cardiomyopathy.